D. Kereiakes

Publications649
h-index101
Citations49,090
Highly Influential Citations1,239
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • E. Topol
  • 1,628 Publications, 139,147 Citations
  • G. Stone
  • 2,317 Publications, 97,102 Citations
  • R. Califf
  • 1,762 Publications, 145,627 Citations
  • P. Serruys
  • 1,602 Publications, 92,522 Citations
  • Publications
  • Influence
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery.
BACKGROUND Preliminary reports of studies involving simple coronary lesions indicate that a sirolimus-eluting stent significantly reduces the risk of restenosis after percutaneous coronary… Expand
  • 4,249
  • 137
  • PDF
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients.
BACKGROUND Previous trials have shown that among high-risk patients with aortic stenosis, survival rates are similar with transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve… Expand
  • 2,458
  • 79
  • PDF
ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of…
The American College of Cardiology (ACC)/American Heart Association (AHA) Task Force on Practice Guidelines was formed to make recommendations regarding the diagnosis and treatment of patients with… Expand
  • 2,441
  • 63
  • PDF
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
BACKGROUND Dual antiplatelet therapy is recommended after coronary stenting to prevent thrombotic complications, yet the benefits and risks of treatment beyond 1 year are uncertain. METHODS… Expand
  • 1,232
  • 61
  • PDF
Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate.
The addition of clopidogrel to aspirin treatment reduces ischemic events in a wide range of patients with cardiovascular disease. However, recurrent ischemic event occurrence during dual antiplatelet… Expand
  • 1,032
  • 57
Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial.
CONTEXT The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during coronary balloon angioplasty but has not been widely tested during… Expand
  • 1,124
  • 43
  • PDF
Endothelial dysfunction.
Drs Ganz and Vita 1 and Verma, Buchanan, and Anderson2 have presented persuasive evidence that endothelial function is dynamically regulated and that the endothelium’s vasodilator, antiinflammatory,… Expand
  • 798
  • 36
ACC/AHA guidelines for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction. A report of the American College of Cardiology/American Heart Association…
Preamble......971 I. Introduction ......972 A. Organization of Committee and Evidence Review......972 B. Purpose of These Guidelines......973 C. Overview of the Acute Coronary… Expand
  • 932
  • 35
Everolimus-Eluting Bioresorbable Scaffolds for Coronary Artery Disease.
BACKGROUND In patients with coronary artery disease who receive metallic drug-eluting coronary stents, adverse events such as late target-lesion failure may be related in part to the persistent… Expand
  • 490
  • 29
  • PDF
ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of…
The American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for the management of unstable angina and non–ST-segment elevation myocardial infarction (UA/NSTEMI) were… Expand
  • 2,618
  • 25
  • PDF